Jan. 26 at 12:42 AM
$MCRB Vedanta and the U of Tokyo filed a patent infringement lawsuit against Seres and several Nestlé-related entities on August 20, 2024, in the U.S. District Court for the District of Delaware, related to VOWST® sales in the U.S. A key development occurred on August 13, 2025, when Vedanta’s VE202 ulcerative colitis program failed its Phase 2 COLLECTiVE202 trial. UC was central to Vedanta’s position, and this outcome weakened its leverage and improved the chances of a settlement on more favorable terms for Nestlé and Seres. In December 2025, the court dismissed several Nestlé defendants for lack of jurisdiction but kept SPN in the case. Around that time, Seres shares rose to near
$30, likely reflecting settlement expectations. In my view, delays in the settlement hurt Vedanta since legal costs keep rising. Once a settlement is announced, I expect Seres’s share price to quickly return to its November highs. This is my research only, you do your own.
